Denali Therapeutics Inc .'s recent unveiling of 11 deals provides the first glimpse of how the company plans to deploy its nearly $350 million war chest to target neurodegenerative diseases. The company has previously said...

Fidelity Biosciences Research Initiative has helped create a neurodegenerative disease company that could serve as a repository for the discoveries stemming from seed investments in academia that FBRI has quietly been making for the past...

Neurodegenerative disease company Denali Therapeutics Inc. (San Francisco, Calif.) raised $217 million in an untranched series A round -- the second largest series A financing in the industry's history. Investors included Fidelity Biosciences; Arch Venture...